SAN FRANCISCO (EGMN) - An ambitious European trial failed to show any significant differences in overall survival among early-stage lung cancer patients randomized to receive either surgery alone or surgery in combination with preoperative or adjunctive chemotherapy.Results of the much-awaited NATCH (Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-Small Cell Lung Cancer) trial were presented Aug. 3 at the World Conference on Lung Cancer.In all, 624 patients with clinical stage...